Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Lilly, Strides Arcolab in emerging markets collaboration
January 2013
SHARING OPTIONS:

BANGALORE, IndiaŚStrides Arcolab Ltd., along with Eli Lilly & Co., has announced a collaboration to expand delivery of cancer medicines in the emerging markets. Per the agreement, Lilly will in-license a portfolio of branded generic injectable and oral cancer medicines from Agila Specialties, Strides Arcolab's specialties division. Agila Specialties will manufacture the medicines, which Lilly will register and market in several geographies across emerging markets. The agreement includes 10 medicines initially, and Lilly has the right to add additional branded generic oncology products in the future.

Financial details were not disclosed.

"We are delighted to partner with Eli Lilly to expand its branded generics platform with high-quality oncology products that will benefit from Lilly's strong global presence in key markets," Arun Kumar, founder and group CEO of Strides Arcolab, said in a press release.


 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.